| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Alan Lewis last filed a Form 4 in June 2020, as Director at BMRN. Alan Lewis's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 25,590 shares of BMRN. The BMRN filings lean toward selling, a net 11,700 shares.
Alan Lewis has 12 Form 4 filings on record from December 2015 to June 2020, across 2 companies: Director at Assembly Biosciences (ASMB), 2015–2020; Director at Biomarin Pharmaceutical (BMRN), 2016–2019.
The 16 reported transactions were 8 option or other derivative awards, 4 stock awards, 3 open-market sales and 1 option exercise.
Counted by filing, the open-market trades come to no purchases and 2 sales worth about $1.2M.
The largest open-market sale was 7,500 shares of BMRN at an average $99.11 on August 28, 2018, about $743K.
Shares as reported in the last Form 4 for each company; the most recent is from June 2020. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.